Last updated: March 7, 2026
What is NDC 00096-0709?
NDC 00096-0709 corresponds to Vancomycin Hydrochloride, a glycopeptide antibiotic used to treat severe bacterial infections, including MRSA (methicillin-resistant Staphylococcus aureus). It is available in intravenous (IV) formulations for hospital and outpatient use.
Market Size and Trends
Current Market Environment
- Global market value: Estimated at $450 million in 2022.
- Growth rate: Compound annual growth rate (CAGR) projected at 3.5% from 2023 to 2028.
- Regional distribution: North America accounts for roughly 60% of sales, driven by high antibiotic usage in hospitals. Europe follows with 25%. The rest of the world accounts for 15%, with rising adoption in Asia-Pacific.
Disease Prevalence
- The global incidence of bacterial infections treated with vancomycin is approximately 21 million cases annually, with hospital-acquired infections constituting a significant share.
- Increased concern over MRSA prevalence has maintained steady demand for vancomycin.
Market Drivers
- Rising antibiotic resistance offers continued demand for potent antibiotics like vancomycin.
- Growing hospital admission rates for bacterial infections.
- Expansion into outpatient intravenous therapy settings.
Market Challenges
- The availability of generic formulations reduces prices and profit margins.
- Increased awareness of vancomycin-associated nephrotoxicity prompts monitoring and limits use.
- Antibiotic stewardship programs restrict widespread empirical use.
Competitive Landscape
Key Players
| Company |
Market Share |
Key Products |
Notes |
| Pfizer (Vancocin) |
~55% of branded market |
Vancocin (brand) |
Remains a primary branded product despite generic competition |
| Sandoz (generic) |
~40% |
Vancomycin hydrochloride (generics) |
Significant share, price competition influences revenue |
| Others |
~5% |
Various regional generics |
Less impactful |
Patent and Regulatory Status
- The original patent for Vancocin expired in 2006.
- Multiple generics entered the market post-patent expiry.
- FDA approved biosimilars and generics continue to expand availability.
Price Trends and Projections
Historical Pricing
| Year |
Average Price per 500 mg vial (USD) |
Market Share of Brand/Gens |
Notes |
| 2018 |
$125 |
55% (Pfizer Vancocin) |
Patent protected, higher price point |
| 2020 |
$115 |
Increasing generics |
Patent expiration reduces branded pricing |
| 2022 |
$102 |
Predominantly generic |
Mass adoption of generics, price erosion |
Future Price Projections (2023-2028)
- The average price per 500 mg vial is expected to decline further, reaching approximately $90-$95 by 2028, primarily due to increased generic competition and commoditization.
- Prices may stabilize or slightly increase in regions with limited generic penetration or where biosimilars are introduced.
Factors Influencing Price Trajectory
- Market saturation of generics: Drives prices downward.
- New formulations: Extended-release versions or oral formulations could command premium pricing if approved.
- Regulatory changes: Policies favoring generic substitution will further pressure prices.
- Supply chain disruptions: Can temporarily inflate prices, especially during global crises such as pandemics.
Investment and Commercial Implications
- For pharmaceutical companies, investing in novel formulations, diagnostics for monitoring toxicity, or resistance mitigation could increase market share.
- Generics manufacturers benefit from cost-effective manufacturing and broad distribution channels.
Summary of Key Data
| Aspect |
Data Points |
| Market size (2022) |
$450 million |
| CAGR (2023-2028) |
3.5% |
| Regional share |
North America 60%, Europe 25%, Asia-Pacific 10%, Rest 5% |
| Price per 500 mg vial (2022) |
~$102 |
| Estimated price (2028) |
~$90–$95 |
Key Takeaways
- The vancomycin market remains steady, fueled by bacterial infection prevalence and resistance issues.
- Market growth is tempered by generic competition and pricing pressures.
- Price per vial decreased from approximately $125 in 2018 to $102 in 2022, with a downward trend expected.
- Market players should focus on formulations, stewardship, and resistance management to sustain margins.
- Regulatory and supply chain dynamics significantly influence pricing and availability.
FAQs
1. How does the patent status impact vancomycin pricing?
Patent expiry in 2006 led to widespread generic entry, reducing prices and increasing accessibility.
2. What is the main driver behind vancomycin demand?
The rise of bacterial infections resistant to other antibiotics, especially MRSA, maintains steady demand.
3. Are biosimilars or generics explicitly impacting the market?
Yes, generics dominate the market since patent expiration, leading to price erosion.
4. Could new formulations influence long-term prices?
Potentially. Extended-release or oral formulations could command higher prices if approved but are not yet prevalent.
5. How vulnerable is the market to antibiotic stewardship policies?
Stewardship programs that restrict empirical use could limit growth but also improve targeted use, stabilizing demand.
References
[1] MarketsandMarkets. (2023). Vancomycin Market – Global Forecast to 2028.
[2] IQVIA. (2022). Market Trends Report for Antibiotics.
[3] U.S. Food and Drug Administration. (2023). Approved Antibiotics and Patent Expiry Dates.
[4] Statista. (2022). Antibiotic Market Revenue Worldwide.
[5] World Health Organization. (2022). Global Antibiotic Resistance Surveillance System.
